SeaCrest Wealth Management LLC Sells 352 Shares of Moderna, Inc. (NASDAQ:MRNA)

SeaCrest Wealth Management LLC trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 5.1% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 6,617 shares of the company’s stock after selling 352 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Moderna were worth $705,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in MRNA. Allworth Financial LP increased its position in Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after purchasing an additional 101 shares during the period. TIAA Trust National Association increased its position in Moderna by 2.3% during the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after purchasing an additional 102 shares during the period. Sound Income Strategies LLC increased its position in Moderna by 17.8% during the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after purchasing an additional 115 shares during the period. EverSource Wealth Advisors LLC increased its position in Moderna by 32.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after purchasing an additional 116 shares during the period. Finally, Mayfair Advisory Group LLC increased its position in Moderna by 6.0% during the 1st quarter. Mayfair Advisory Group LLC now owns 2,164 shares of the company’s stock valued at $231,000 after purchasing an additional 122 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,296 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $210,561.12. Following the transaction, the insider now owns 10,623 shares in the company, valued at approximately $1,725,918.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Moderna news, insider Shannon Thyme Klinger sold 1,296 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $210,561.12. Following the transaction, the insider now owns 10,623 shares in the company, valued at approximately $1,725,918.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 705 shares of the company’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $101.93, for a total transaction of $71,860.65. Following the transaction, the chief financial officer now owns 5,048 shares in the company, valued at approximately $514,542.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 396,255 shares of company stock worth $54,593,731. Company insiders own 15.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Evercore ISI reissued an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research report on Thursday, June 27th. Royal Bank of Canada boosted their target price on shares of Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a report on Monday, June 3rd. Oppenheimer boosted their target price on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, June 12th. William Blair restated a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Finally, UBS Group boosted their target price on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $134.02.

Moderna Trading Down 1.0 %

Shares of Moderna stock opened at $115.95 on Thursday. The firm’s 50-day moving average is $134.68 and its 200 day moving average is $112.65. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. Moderna’s revenue was down 91.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.19 EPS. As a group, equities analysts anticipate that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.